Re­gen­eron of­fers a pos­i­tive look at the first cut of its Covid-19 an­ti­body cock­tail — but just how well does it pro­tect a vul­ner­a­ble group?

On the heels of a dis­ap­point­ing per­for­mance by Eli Lil­ly’s an­ti­body tar­get­ing the coro­n­avirus, Re­gen­eron is now step­ping up with ev­i­dence that its an­ti­body cock­tail — at the high dose — has a sig­nif­i­cant im­pact on slash­ing vi­ral load in pa­tients most at risk of a dan­ger­ous re­ac­tion. And they plan to hus­tle the first cut of the da­ta to reg­u­la­tors, who have al­ready shown an ea­ger­ness in get­ting drugs out to com­bat Covid-19 as quick­ly as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER